Evidence map›Paper›PMID 28811252›Full record

ArticleHuman pathology2018

Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.

Shingo Inaguma, Jerzy Lasota, Zengfeng Wang, Piotr Czapiewski, Renata Langfort, Janusz Rys, Joanna Szpor, Piotr Waloszczyk, Krzysztof Okoń, Wojciech Biernat and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Article
  3. Breaking Immunosuppression to Enhance Cancer Stem Cell-Targeted Immunotherapy.International journal of biological sciences · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Immunotherapy approaches for malignant pleural mesothelioma.Nature reviews. Clinical oncology · 2022
    Review
  11. Review
  12. Article
  13. Article
  14. The efficacy of immune checkpoint inhibitors in thoracic malignancies.European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
  15. CAR-T therapy: Prospects in targeting cancer stem cells.Journal of cellular and molecular medicine · 2021
    Review
  16. Review
  17. Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Observational
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 4 countries.

Shingo InagumaLaboratory of Pathology, National Cancer Institute, Bethesda, MD 20892; Department of Pathology, Aichi Medical University School of Medicine, Nagakute, Japan 480-1195. Electronic address: inaguma@aichi-med-u.ac.jp.
Jerzy LasotaLaboratory of Pathology, National Cancer Institute, Bethesda, MD 20892.
Zengfeng WangLaboratory of Pathology, National Cancer Institute, Bethesda, MD 20892.
Piotr CzapiewskiDepartment of Pathomorphology, Medical University of Gdansk, Gdansk, Poland 80-210; Department of Pathology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany 39106.
Renata LangfortDepartment of Pathology, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland 01-138.
Janusz RysDepartment of Tumor Pathology, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Krakow Branch, Poland 31-115.
Joanna SzporDepartment of Pathomorphology, Jagiellonian University, Krakow, Poland 31-007.
Piotr WaloszczykIndependent Laboratory of Pathology, Zdunomed, Szczecin, Poland 70-891.
Krzysztof OkońDepartment of Pathomorphology, Jagiellonian University, Krakow, Poland 31-007.
Wojciech BiernatDepartment of Pathomorphology, Medical University of Gdansk, Gdansk, Poland 80-210.
Hiroshi IkedaDepartment of Pathology, Aichi Medical University School of Medicine, Nagakute, Japan 480-1195.
David S SchrumpThoracic and GI Oncology Branch, National Cancer Institute, Bethesda, MD 20892.
Raffit HassanThoracic and GI Oncology Branch, National Cancer Institute, Bethesda, MD 20892.
Markku MiettinenLaboratory of Pathology, National Cancer Institute, Bethesda, MD 20892.
National Cancer Institute · USGdańsk Medical University · PLJagiellonian University · PLAichi Medical University · JPThe Maria Sklodowska-Curie National Research Institute of Oncology · PL

Funding

Immunohistochemical and genomic analysis of tumorsZIABC011427 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MIETTINEN, MARKKU · 2012 to 2025
$24.0M
Targeting the Epigenome for Lung Cancer TherapyZIASC010093 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI SCHRUMP, DAVID · 2009 to 2025
$11.9M
Intramural NIH HHS ZIA BC011427
6 · The paper itself

Abstract

Diffuse malignant mesothelioma of the pleura is a highly aggressive tumor typically associated with short survival. ALCAM (CD166), a type I transmembrane protein, is a member of the immunoglobulin superfamily. In normal cells, ALCAM regulates physiological processes such as angiogenesis and immune response. In cancer, it is associated with neoplastic progression, including invasion, migration, and metastasis. Furthermore, ALCAM is considered one of the cancer stem cell markers such as ALDH1 (ALDH1A1) and SALL4. The PD-L1 (CD274)/PD-1 (PDCD1, CD279) pathway is crucial for the modulation of immune responses in normal cells. Nevertheless, pathologic activation of the PD-L1/PD-1 pathway participates in immune evasion by tumor cells. Many PD-L1-expressing tumor cells have been identified in different types of cancer, including malignant mesothelioma. In this study, 175 well-characterized primary diffuse pleural mesotheliomas, including the epithelioid (n = 148), biphasic (n = 15), and sarcomatoid (n = 12) histotypes, were evaluated immunohistochemically for cancer stem cell markers (ALCAM, ALDH1, and SALL4) and PD-L1 expression. Twenty-five percent of the mesotheliomas (43/175) expressed ALCAM, whereas ALDH1 and SALL4 positivity was seen in 1% to 2% of cases. Thirty-three percent of the analyzed tumors (57/175) contained PD-L1-positive cells. Overall survival was significantly decreased in the cohort of patients with ALCAM- or PD-L1-positive tumors (both P < .01). Furthermore, the multivariate Cox hazards regression analysis identified ALCAM and PD-L1 (both P < 0.01) as potential independent risk factors. Thus, a combination of these 2 markers might be useful for prognostication and planning the treatment of patients with malignant pleural mesothelioma.

Indexed as

Activated-Leukocyte Cell Adhesion MoleculeAdultAgedAntigens, CDB7-H1 AntigenBiomarkers, TumorCell Adhesion Molecules, NeuronalFemaleFetal ProteinsHumansLung NeoplasmsMaleMesotheliomaMesothelioma, MalignantMiddle AgedPleural NeoplasmsActivated-Leukocyte Cell Adhesion MoleculeALCAM protein, humanAntigens, CDB7-H1 AntigenBiomarkers, TumorCD274 protein, humanCell Adhesion Molecules, NeuronalFetal ProteinsALCAM, activated leukocyte cell adhesion molecule (CD166)ALDH1A1, aldehyde dehydrogenase 1A1 (ALDH1)MPM, malignant pleural mesotheliomaPD-L1, programmed cell death ligand 1 (CD274)SALL4, spalt-like transcription factor 4

Identifiers

PMID28811252
PMCPMC5748003
OpenAlexW2749532644

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.